Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $1,000.0 million
Deal Type : Acquisition
Radionetics Oncology Enters Into Strategic Agreement With Lilly
Details : Through the acquisition, Eli Lilly will leverage small molecule radioligand therapeutics targeting GPCRs using the Radionetics proprietary discovery platform for treating neoplasms.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $140.0 million
July 01, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $1,000.0 million
Deal Type : Acquisition
Radionetics Raises $52.5M Series A to Advance Radiopharmaceutical Pipeline and CEO
Details : Radionetics plans to use the proceeds to advance its pipeline of potent, small molecule radiopharmaceuticals targeting novel G-protein coupled receptors (GPCRs) for a broad range of cancers.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 03, 2024
GordonMD® Announces Investment in Radiopharmaceutical Biotech Radionetics Oncology
Details : The financing will focus on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications by using company's platform technology which uses small molecule targeting to deliver radioisotopes to a broad ...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 17, 2023
LOOKING FOR A SUPPLIER?